Patents by Inventor Rajinder Singh

Rajinder Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 6-5 fused rings as C5a inhibitors
    Patent number: 11384079
    Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: July 12, 2022
    Assignee: ChemoCentryx, Inc.
    Inventors: Pingchen Fan, Christopher W. Lange, Rebecca M. Lui, Viengkham Malathong, Venkat Reddy Mali, Sreenivas Punna, Rajinder Singh, Hiroko Tanaka, Yibin Zeng, Penglie Zhang
  • Treatment of focal segmental glomerulosclerosis with CCR2 antagonists
    Patent number: 11382915
    Abstract: Provided herein are methods of treating focal segmental glomerulosclerosis, said methods include administering to a subject in need thereof a therapeutically effective amount of a CCR2 antagonist. In some embodiments, the CCR2 antagonist is used in monotherapy. In some embodiments, the CCR2 antagonist is used in combination therapy. In some embodiments, the additional therapeutic agent is a RAAS blocker and/or an endothelin receptor inhibitor. The CCR2 antagonist may have the structure of formula (I).
    Type: Grant
    Filed: August 11, 2020
    Date of Patent: July 12, 2022
    Assignee: ChemoCentryx, Inc.
    Inventors: Zhenhua Miao, Thomas J. Schall, Rajinder Singh
  • Gene controlling shell phenotype in palm
    Patent number: 11371104
    Abstract: Nucleic acid sequences for predicting and controlling shell phenotype in palm.
    Type: Grant
    Filed: March 24, 2020
    Date of Patent: June 28, 2022
    Assignee: Malaysian Palm Oil Board
    Inventors: Rajinder Singh, Leslie Low Eng Ti, Leslie Ooi Cheng Li, Meilina Ong Abdullah, Rajanaidu Nookiah, Ravigadevi Sambanthamurthi, Steven W. Smith, Nathan D. Lakey, Rob Martienssen, Jared Ordway, Michael Hogan
  • Pyrazole compounds and methods for making and using the compounds
    Patent number: 11370808
    Abstract: Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: June 28, 2022
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Ryan Kelley, Hui Li, Thilo Heckrodt, Yan Chen, Darren McMurtrie, Kin Tso, Vanessa Taylor, Rajinder Singh, Rose Yen, Jack Maung
  • BENZAZOLE COMPOUNDS AND METHODS FOR MAKING AND USING THE COMPOUNDS
    Publication number: 20220185804
    Abstract: Disclosed are novel benzazole compounds and compositions comprising the compounds. The compounds are useful as kinase inhibitors including interleukin receptor associated kinases (IRAK) inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Application
    Filed: March 7, 2022
    Publication date: June 16, 2022
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Rose Yen, Yan Chen, Rajinder Singh, Vanessa Taylor
  • INDANE-AMINES AS PD-L1 ANTAGONISTS
    Publication number: 20220175746
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: August 30, 2021
    Publication date: June 9, 2022
    Inventors: Christopher LANGE, Sreenivas PUNNA, Rajinder SINGH, Ju YANG, Penglie ZHANG
  • TGF-beta inhibitors
    Patent number: 11352360
    Abstract: Disclosed are imidazole and thiazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein X, A, Z, R1 and R? are as described herein. In certain embodiments, a compound disclosed herein inhibits TGF-?, and can be used to treat disease by blocking TGF-? signaling.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: June 7, 2022
    Assignees: Rigel Pharmaceuticals, hic., Bristol-Myers Squibb Company
    Inventors: Todd Kinsella, Marina Gelman, Hui Hong, Ihab S. Darwish, Rajinder Singh, Jiaxin Yu, Robert M. Borzilleri, Upender Velaparthi, Peiying Liu, Chetan Padmakar Dame, Hasibur Rahaman, Jayakumar Sankara Warrier
  • Method of Treating Focal Segmental Glomerulosclerosis
    Patent number: 11324736
    Abstract: A method of treating focal segmental glomerulosclerosis with a compound of Formula I is provided. FSGS may be primary (no known cause) or secondary. The secondary FSGS may be associated with infections or viruses such as HIV, diseases such as sickle cell disease or lupus, toxins or drugs such as anabolic steroids, heroin or pamidronate, nephron loss and hyperfiltration, such as with chronic pyelonephritis and reflux, morbid obesity, or diabetes mellitus.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: May 10, 2022
    Assignee: ChemoCentryx, Inc.
    Inventors: Zhenhua Miao, Thomas Schall, Rajinder Singh
  • METHODS OF TREATING HIDRADENITIS SUPPURATIVA
    Publication number: 20220125775
    Abstract: Provided herein are methods for treating a subject suffering from a cutaneous neutrophilic inflammatory disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein each variable position is as defined herein. In some embodiments, the cutaneous neutrophilic inflammatory disease is Hidradenitis suppurativa (HS).
    Type: Application
    Filed: October 27, 2021
    Publication date: April 28, 2022
    Inventors: Shijie LI, Rajinder Singh, Thomas J. Schall, Peter Staehr
  • MACROCYCLIC IMMUNOMODULATORS
    Publication number: 20220119405
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I) or (II): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, R6c, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: June 3, 2021
    Publication date: April 21, 2022
    Inventors: Viengkham MALATHONG, Jeffrey McMAHON, Darren J. McMURTRIE, Sreenivas PUNNA, Howard S. ROTH, Rajinder SINGH, Penglie ZHANG
  • Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor
    Patent number: 11304952
    Abstract: The present disclosure is drawn to the combination therapy of a Chemokine Receptor 2 (CCR2) antagonist and a PD-1 and/or PD-L1 inhibitor in the treatment of cancer.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: April 19, 2022
    Assignee: ChemoCentryx, Inc.
    Inventors: James J. Campbell, Zhenhua Miao, Thomas J. Schall, Israel Charo, Shijie Li, Christine Marie Janson, Rajinder Singh, Karen Ebsworth
  • SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20220112176
    Abstract: The present disclosure relates generally to compounds useful for the treatment and/or enhancement of cognitive function and negative symptoms associated with central nervous system disorders where the circuitry involving fast spiking PV+ interneurons and the production of cortical gamma oscillations is disrupted. The subject disclosure enables the manufacture of medicaments as well as compositions containing same for use in methods of therapy and prophylaxis of cognitive dysfunction and negative symptoms.
    Type: Application
    Filed: October 30, 2019
    Publication date: April 14, 2022
    Inventors: Hamish Toop, Dharam Paul, Rajinder Singh, Erin Smith, Patrick Bazzini, Jean-Marie Contreras, Christophe Morice, Laurent Schaeffer, Celine Michaut-Simon, Florence Chery, Fabrice Garrido
  • Benzazole compounds and methods for making and using the compounds
    Patent number: 11299486
    Abstract: Disclosed are novel benzazole compounds and compositions comprising the compounds. The compounds are useful as kinase inhibitors including interleukin receptor associated kinases (IRAK) inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: April 12, 2022
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rose Yen, Yan Chen, Rajinder Singh, Vanessa Taylor
  • FREE BASE CRYSTALLINE FORM OF A COMPLEMENT COMPONENT C5a RECEPTOR
    Publication number: 20220096453
    Abstract: Provided herein is a free base crystalline form of a complement component 5a receptor having the formula of Compound 1 Also provided herein are pharmaceutical compositions and methods of treatment using the crystalline free base form of Compound 1 described herein.
    Type: Application
    Filed: May 4, 2021
    Publication date: March 31, 2022
    Inventors: Rajinder SINGH, Kwok YAU, Yibin ZENG, Penglie ZHANG, Rebecca M. LUI, Antoni KRASINSKI
  • DIRECT AMPK ACTIVATORS
    Publication number: 20220098175
    Abstract: Disclosed are benzimidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein R1, R2, R3, R4, Y and X are as described herein. In certain embodiments, a compound disclosed herein activates AMPK, and can be used to treat disease by activating the AMPK pathway.
    Type: Application
    Filed: October 13, 2021
    Publication date: March 31, 2022
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Simon Shaw, Xiang Xu, Sarkiz Issakani, Rajinder Singh, Yasumichi Hitoshi, Matthew Duncton, Nan Lin
  • COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
    Publication number: 20220098181
    Abstract: The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.
    Type: Application
    Filed: November 2, 2021
    Publication date: March 31, 2022
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Sambaiah Thota, David Carroll, Ankush Argade, Kin Tso, Arvinder Sran, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Vanessa Taylor, Robin Cooper, Rajinder Singh, Brian Wong
  • Nrf2 activating compounds and uses thereof
    Patent number: 11279686
    Abstract: Aspects of the present disclosure include compounds that activate Nrf2. Such compounds find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: March 22, 2022
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Matthew Duncton, Rajinder Singh
  • NOVEL SALTS AND POLYMORPHIC FORM OF BEMPEDOIC ACID
    Publication number: 20220081385
    Abstract: The present invention relates to novel pharmaceutically acceptable salts of Bempedoic acid, novel intermediates of Bempedoic acid, novel crystalline form of Bempedoic acid and novel processes for the preparation of Bempedoic acid or its intermediates thereof.
    Type: Application
    Filed: December 27, 2019
    Publication date: March 17, 2022
    Inventors: Navnath Ambadas Kadam, Rohidas Shivaji Sulake, Rajinder Singh Siyan, Nandu Baban Bhise, Girij Pal Singh, Rajesh Harishankar Vyas
  • METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS
    Publication number: 20220073536
    Abstract: The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lupus erythematosus and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.
    Type: Application
    Filed: November 19, 2021
    Publication date: March 10, 2022
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Ankush Argade, Hui Li, Somasekhar Bhamidipati, David Carroll, Catherine Sylvain, Jeffrey Clough, Holger Keim
  • Triaryl compounds for treatment of PD-L1 diseases
    Patent number: 11266643
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1a, R1b, R1c, R1d, R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: March 8, 2022
    Assignee: ChemoCentryx, Inc.
    Inventors: Pingchen Fan, Christopher Lange, Venkat Reddy Mali, Darren J. McMurtrie, Viengkham Malathong, Sreenivas Punna, Rajinder Singh, Ju Yang, Yibin Zeng, Penglie Zhang